Nobio

Advanced Antimicrobial Solutions for Medical, Dental, and Consumer Products

Industrial Technologies
Active
Mature Kadima Zoran, Israel Founded 2015
Last updated 2026-06-18
Total raised
$4.0M
Last: 2021-01
Stage
Mature
Founded
2015
Headcount
28
HQ
Kadima Zoran, Israel
Sector
Industrial Technologies

About

Nobio develops long-term antibacterial and antiviral solutions for medical, dental, and consumer products. The company commercializes its antimicrobial technology both through its own products and through partnerships with industry leaders. Nobios core technology consists of extremely potent particles covered with a high concentration of highly active antimicrobial molecules that kill a wide range of microorganisms (bacteria, viruses, fungi, etc.) on contact. The Nobio particles can be permanently embedded in, or used as a coating on, many products and materials, providing powerful bioprotection for life. In September 2019, the company received FDA approval to market Infinix, its line of antibacterial products for dental fillings. In response to COVID-19, Nobio is also implementing its technology in personal protective equipment (PPE) and surface coatings. Nobio is working with several industry leaders to incorporate its technology into their medical, dental, and consumer products. Nobio also received a grant from the Israeli Innovation Authority for its work on PPE and is involved in discussions with potential partners for commercialization.

Funding history · 4 rounds · $4.0M total

2021-01
Undisclosed
2020-04
2018-08
2016-11
Grant $200K

Q&A

What is Nobio's primary focus?
Nobio develops long-term antibacterial and antiviral solutions for medical, dental, and consumer products, commercializing its technology through its own products and industry partnerships.
When was Nobio founded?
Nobio was founded in July 2015.
What significant regulatory approval did Nobio receive in 2019?
In September 2019, Nobio received FDA approval to market Infinix, its line of antibacterial products for dental fillings.
What is Nobio's total funding raised to date?
Nobio has raised a total of $4,005,000 USD.
Which investors participated in Nobio's August 2018 funding round?
In August 2018, Nobio received funding from Dr. Ole Jensen and aMoon Fund.
What is the core technology behind Nobio's solutions?
Nobio's core technology involves potent particles covered with highly active antimicrobial molecules that kill a wide range of microorganisms on contact. These particles can be permanently embedded in or used as a coating on various products and materials.
How did Nobio respond to the COVID-19 pandemic?
In response to COVID-19, Nobio began implementing its technology in personal protective equipment (PPE) and surface coatings, and received a grant from the Israeli Innovation Authority for its work on PPE in April 2020.

Team · 1

Founder · Founder
LinkedIn ↗

Sectors & technology

Primary sector
Industrial Technologies
Sub-sectors
Industrial TechnologiesMaterial Innovations & Applications
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareProvidersLaboratoriesIndustrial ManufacturingManufacturing Facilities
Business model
B2BB2B2C

Highlights

1 Patents

Tags

bioconvergencedentistspharmaceuticalsnanotechnologymedical-devicesdentalbiotechnologymaterialsmedical-equipmentmicrobiologypackaging-and-containerstextilemanufacturing-facilitieshygienesurface-and-coatingshvachospitals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)